Kushanda Kwakanyanya kweCD7 CAR-T Therapy yeB-Cell Malignancies: Kubudirira Mukurapa Kenza
Ongororo yazvino inoratidza kushanda uye kuchengetedzeka kweCD7 CAR-T cell therapy mukurapa B-cell acute lymphoblastic leukemia (B-ALL) yakadzoka kana kuti isingadzoreki uye T-cell lymphoblastic lymphoma (T-LBL). Chidzidzo ichi chakaitwa neBIOOCUS pamwe chete neLu Daopei Hospital, chinoratidza mhedzisiro inovimbisa kuvarwere, ichipa imwe nzira ine simba pane chemotherapy yechinyakare.
Mukuvandudzwa kunonakidza kwe Kurapa Kenza, BIOOCUS, pamwe chete neLu Daopei Hospital, vakaburitsa tsvakiridzo itsva pamusoro pekushandiswa kweCD7 chimeric antigen receptor (CAR) T-cell therapy. Iyi nzira itsva, yakanangana neB-cell acute lymphoblastic leukemia (B-ALL) uye T-cell lymphoblastic lymphoma (T-LBL) inodzokera shure kana kuti isingadzoreki, inoratidza kushanda zvakanaka uye kuchengetedzeka, zvichivandudza zvakanyanya mhedzisiro yemurwere.
Chidzidzo ichi, chakaburitswa mumagazini ine mukurumbira, chaisanganisira kuenzanisa varwere vaigamuchira kurapwa kweCD7 CAR-T kwakazoteverwa nekubatanidzwa ne allogeneic hematopoietic hematopoietic stem cell transplantation (allo-HSCT) kune avo vairapwa ne chemotherapy vasati vaisirwa. Zvakawanikwa mukutsvaga zvinoratidza kuti varwere vakawana complete remission (CR) neCD7 CAR-T therapy vaive nemigumisiro yakafanana yekurarama kwenguva refu neavo vairapwa ne chemotherapy yechinyakare. Chinokosha ndechekuti, chidzidzo ichi hachina kuwana kuwedzera kukuru kwematambudziko epashure pekuisirwa, akadai se graft-versus-host disease (GVHD), hutachiona, kana zvimwe zviitiko zvakaipa.
Zvinhu zvikuru zvekudzidza zvinosanganisira:
- Mwero Wakakwana weKuregererwa: Kurapa kweCD7 CAR-T kwakaratidza mwero unoshamisa wekuregererwa kwechirwere chose, varwere vanopfuura 97% vakabvuma kurapwa zvakanaka.
- Nhoroondo Yekuchengetedza: Pasinei nenzira itsva yekushandisa CAR-T therapy, kurapwa kwacho kwakashivirirwa zvakanaka, pasina migumisiro yakawanda uye hapana kuwedzera kukuru kweGVHD yepamusoro kana mamwe matambudziko akakomba.
- Kubudirira Mushure mekuisirwa: Varwere vairapwa neallo-HSCT mushure mekupedza CR neCD7 CAR-T therapy vakawana kupona kwakanaka kwese (OS) uye kupona kusina leukemia (LFS), zvakafanana nekurapwa kwechinyakare kwakavakirwa pachemotherapy.
Tsvagiridzo iyi inomiririra danho guru munyaya dze Kurapa Kenza Nekudzivirira Kurwara, ichipa tariro kuvarwere vane mafomu e leukemia ne lymphoma anodzoka kana kuti asingachadi kurapwa. BIOOCUS inoramba yakazvipira kusimudzira miganhu ye CAR-T therapy, ichipa mhinduro itsva kuvarwere vakapedza nzira dzekurapa dzechinyakare. Sezvo nyika ichigamuchira mishonga iyi yemazuva ano, BIOOCUS iri pamberi mukugadzira mishonga inounza shanduko chaiyo kumhedzisiro yemurwere.